Benzinga | Mar 11, 2021 01:17PM EST

Harpoon Therapeutics Announces Poster Presentations At AACR Annual Meeting 2021 Apr. 10

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting Week 1 will be held virtually from April 10-15, 2021. Posters will be available on Harpoon's website following the presentations.



Full abstracts of the following presentations are available online at www.aacr.org:

Title: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia

Abstract #: 913

Presenter: Richard J. Austin, Ph.D.

Session Category: Experimental and Molecular Therapeutics

Session Title: PO.ET01.01 - Antibody Technologies

Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT

Title: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets

Abstract #: 933

Presenter: S. Jack Lin, Ph.D.

Session Category: Experimental and Molecular Therapeutics

Session Title: PO.ET01.02 - Biochemical Modulators of the Therapeutic Index

Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT

Title: Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models

Abstract #: 1573

Presenter: Mary Ellen Molloy, Ph.D.

Session Category: Immunology

Session Title: PO.IM02.02 - Combination Immunotherapies

Date/time: April 10, 2021, 8:30 a.m - 11:59 p.m. EDT